Skip to main content
Premium Trial:

Request an Annual Quote

Lonza Acquires Transfection Systems Maker Amaxa

NEW YORK (GenomeWeb News) – Swiss firm Lonza said today that it has acquired cell research products firm amaxa for an undisclosed sum.
 
Lonza expects the acquisition to strengthen the cell discovery business of its Lonza Bioscience division, which supplies primary cells and serves a similar customer base to that of amaxa. Cologne, Germany-based amaxa’s Nucleofection technology is used to transfer DNA or RNA into cells that are considered difficult to transfect.
 
Lonza said that the acquisition will enhance the profit margins and growth rates for Lonza Bioscience. The deal is subject to regulatory approval and is expected to be completed early in the third quarter of this year.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.